577P Results of the phase Ib study of NC410 combined with pembrolizumab in MSS/MSI-L colorectal cancer patients
Christenson E, Kazmi S, Mahadevan D, Sohal D, Manda S, Martz A, Kordahi S, Zika M, Kothari P, Kahan S, Barbu E, Morawski A, Flies D, Langermann S, Chisamore M, Fu S, Wadlow R, Guha U, Myint H, Le D. 577P Results of the phase Ib study of NC410 combined with pembrolizumab in MSS/MSI-L colorectal cancer patients. Annals Of Oncology 2024, 35: s468. DOI: 10.1016/j.annonc.2024.08.646.Peer-Reviewed Original ResearchBCAM (basal cell adhesion molecule) protein expression in different tumor populations
Burela S, He M, Trontzas I, Gavrielatou N, Schalper K, Langermann S, Flies D, Rimm D, Aung T. BCAM (basal cell adhesion molecule) protein expression in different tumor populations. Discover Oncology 2024, 15: 381. PMID: 39207605, PMCID: PMC11362396, DOI: 10.1007/s12672-024-01244-1.Peer-Reviewed Original ResearchPD-L1 expressionBasal cell adhesion moleculePD-L1Quantitative immunofluorescenceAssociated with better OSPD-L1 protein expressionCancer typesBladder urothelial tumorsProtein expressionMultiple immune checkpointsHead and neckMultiple tumor typesEvidence of hypermethylationImmune checkpointsImmunotherapy responseCell adhesion moleculesTumor typesValidation cohortTumor populationCancer patientsTumorPredictive valueAdhesion moleculesNovel biomarkersWidespread expression